Track Mustang Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Mustang Bio, Inc. MBIO · Stock Open Mustang Bio, Inc. in new tab

0.4214 USD
P/E
0.62
EPS
-0.44
P/B
0.30
ROE
-58.12
Beta
2.20
Loading chart...
Key Metrics
Earnings dateNov. 18, 2026
P/E0.62
EPS-0.44
Book Value1.31
Price to Book0.30
% Insiders8.021%
Estimates
Forward P/E-1.13
Forward EPS-0.35

DCF valuation

Model fair value for Mustang Bio, Inc. (MBIO)
Result
Sign in to run the valuation for MBIO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Mustang Bio, Inc. Logo Mustang Bio, Inc. Analysis (MBIO)

United States Health Care Official Website Stock

Is Mustang Bio, Inc. a good investment? Mustang Bio, Inc. (MBIO) is currently trading at 0.4214 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.62. This relatively low multiple may signal that Mustang Bio, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Mustang Bio, Inc. is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -0.35.

Investor FAQ

Does Mustang Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Mustang Bio, Inc.?

Mustang Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -0.44.

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) MBIO
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 4, 2023 1:15
Jan. 16, 2025 1:50
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion